Wuxi International Life-Science Innovation Campus, or iCampus, signed a strategic cooperation agreement with the Hong Kong ...

Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...

In addition, WuXi AppTec drives sustainability by participating in ambitious global frameworks. In 2023, WuXi AppTec joined the Science Based Targets initiative (SBTi) to reduce carbon emissions, and ...

U.S. drugmakers and biotechs have come to rely on Chinese partners. Now, some of them are looking for alternatives as ...

As the Chinese contract manufacturer awaits the U.S. Senate’s consideration of the BIOSECURE Act, it has added 800 new ...

三氟化硼（CAS 7637-07-2）行业调研报告聚焦三氟化硼（CAS 7637-07-2）市场并重点对该市场的历史与预测期市场规模做出了统计与预测，报告显示，2023年全球三氟化硼（CAS 7637-07-2）市场规模为 ...

and Complete Genomics); contract-based research for drug development (WuXi) and biomanufacturing that synthesizes biologics and active pharmaceutical ingredients to produce drugs at scale (WuXi).

Initially, it was suggested that BIO, a membership trade organisation for biotech, had been lobbying on behalf of WuXi AppTec and against the BIOSECURE Act. However, in a reversal, the ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, ...

"We are delighted to receive the 2024 Global CRDMO Company of the Year Award from Frost & Sullivan," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "WuXi AppTec is committed to enhancing our unique ...

WuXi AppTec reported 3Q24 revenue of RMB10.46bn, slightly down 2.0% YoY,and attributable adjusted non-IFRS net profit of RMB2.97bn, down 3.2% YoY.Total non-COVID revenue and non-COVID Chemistry revenu ...